Effectiveness of receiving genetic risk information for cardiovascular disease on health behaviors, psychological responses, and associated risk factor modification in individuals: a systematic review protocol.

IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES JBI evidence synthesis Pub Date : 2024-09-03 DOI:10.11124/JBIES-23-00313

Ruofei Trophy Chen, Vincent Pearson, Orathai Suebkinorn, Lemma N Bulto, Alice Anderson, Adam J Nelson, Sophia Zoungas, Stephen J Nicholls, Robyn A Clark

{"title":"Effectiveness of receiving genetic risk information for cardiovascular disease on health behaviors, psychological responses, and associated risk factor modification in individuals: a systematic review protocol.","authors":"Ruofei Trophy Chen, Vincent Pearson, Orathai Suebkinorn, Lemma N Bulto, Alice Anderson, Adam J Nelson, Sophia Zoungas, Stephen J Nicholls, Robyn A Clark","doi":"10.11124/JBIES-23-00313","DOIUrl":null,"url":null,"abstract":"Objective: This review aims to assess the effectiveness of receiving genetic risk information for cardiovascular disease (CVD) on individual health behaviors, psychological responses, and risk factor modification.Introduction: Advancements in genomics have identified strong genetic predispositions for CVD, leading to the development of CVD genetic risk information. Integrating genetic risk information into clinical practice shows promise in predicting CVD risk and facilitating multifactorial management.Inclusion criteria: This review will focus on randomized controlled trials assessing individual responses to CVD genetic risk information. Participants will be adults aged 18 and older, both with and without CVD. The review will compare the effectiveness of receiving genetic risk information with receiving traditional risk information or no risk information, assessing outcomes such as health behaviors, psychological responses, and risk factor modification.Methods: Cochrane CENTRAL, MEDLINE, Embase and Emcare will be searched for relevant studies. Current or unpublished trials will be searched for in Clinical-Trials.gov and World Health Organization International Clinical Trials Registry Platform. Articles will be screened and assessed for inclusion by 2 independent reviewers. Methodological quality will be assessed using the standardized instrument from JBI. Data will be extracted and synthesized for the objectives of the study. If data are sufficient, a meta-analysis will be conducted; otherwise, the findings will be presented in narrative format, including tables and figures to aid in presentation. The certainty of evidence will be assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach.Review registration: PROSPERO CRD42023390876.","PeriodicalId":36399,"journal":{"name":"JBI evidence synthesis","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JBI evidence synthesis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11124/JBIES-23-00313","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This review aims to assess the effectiveness of receiving genetic risk information for cardiovascular disease (CVD) on individual health behaviors, psychological responses, and risk factor modification.

Introduction: Advancements in genomics have identified strong genetic predispositions for CVD, leading to the development of CVD genetic risk information. Integrating genetic risk information into clinical practice shows promise in predicting CVD risk and facilitating multifactorial management.

Inclusion criteria: This review will focus on randomized controlled trials assessing individual responses to CVD genetic risk information. Participants will be adults aged 18 and older, both with and without CVD. The review will compare the effectiveness of receiving genetic risk information with receiving traditional risk information or no risk information, assessing outcomes such as health behaviors, psychological responses, and risk factor modification.

Methods: Cochrane CENTRAL, MEDLINE, Embase and Emcare will be searched for relevant studies. Current or unpublished trials will be searched for in Clinical-Trials.gov and World Health Organization International Clinical Trials Registry Platform. Articles will be screened and assessed for inclusion by 2 independent reviewers. Methodological quality will be assessed using the standardized instrument from JBI. Data will be extracted and synthesized for the objectives of the study. If data are sufficient, a meta-analysis will be conducted; otherwise, the findings will be presented in narrative format, including tables and figures to aid in presentation. The certainty of evidence will be assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach.

Review registration: PROSPERO CRD42023390876.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

接受心血管疾病遗传风险信息对个人健康行为、心理反应和相关风险因素调整的影响：系统性综述方案。

目的：本综述旨在评估接受心血管疾病（CVD）遗传风险信息对个人健康行为、心理反应和风险因素调整的影响：本综述旨在评估接受心血管疾病（CVD）遗传风险信息对个人健康行为、心理反应和风险因素改变的影响：基因组学的进步发现了心血管疾病的强遗传倾向，从而开发了心血管疾病遗传风险信息。将遗传风险信息纳入临床实践有望预测心血管疾病风险并促进多因素管理：本综述将侧重于评估个人对心血管疾病遗传风险信息反应的随机对照试验。参与者将是 18 岁及以上的成年人，既包括心血管疾病患者，也包括非心血管疾病患者。综述将比较接受遗传风险信息与接受传统风险信息或不接受风险信息的效果，评估健康行为、心理反应和风险因素改变等结果：方法：将在 Cochrane CENTRAL、MEDLINE、Embase 和 Emcare 中检索相关研究。将在 Clinical-Trials.gov 和世界卫生组织国际临床试验注册平台上搜索当前或未发表的试验。文章将由两名独立审稿人筛选和评估是否纳入。方法学质量将使用 JBI 的标准化工具进行评估。将根据研究目标提取和综合数据。如果数据充足，将进行荟萃分析；否则，研究结果将以叙述的形式呈现，包括有助于呈现的表格和图表。证据的确定性将采用建议、评估、发展和评价分级法（GRADE）进行评估：综述注册：prospero crd42023390876。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊